Evidence map›Paper›PMID 41462404›Full record

ArticleJournal of health, population, and nutrition2025

Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.

Takahiro Hiraide, Yoshihiko Suzuki, Satoko Yamamoto, Soroku Yagihashi, Motoaki Sano

Abstract read
In one paragraph

Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takahiro HiraideHDC atlas clinic, Tokyo, Japan. t.hiraide.a6@keio.jp.
Yoshihiko SuzukiHDC atlas clinic, Tokyo, Japan.
Satoko YamamotoHDC atlas clinic, Tokyo, Japan.
Soroku YagihashiHDC atlas clinic, Tokyo, Japan.
Motoaki SanoHDC atlas clinic, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has demonstrated robust efficacy in clinical trials; however, discontinuation rates due to gastrointestinal adverse events have been reported at 6-10% in Western populations. In contrast, our real-world study of 219 Japanese patients revealed a markedly lower discontinuation rate of approximately 1.3%. Dietary questionnaires indicated that patients experienced reduced appetite for high-fat and high-calorie foods while maintaining consumption of low-carbohydrate traditional Japanese foods such as fish and meat, which may have contributed to the low discontinuation rate.

Indexed as

Diabetes Mellitus, Type 2DietGastric Inhibitory PolypeptideHypoglycemic AgentsAdultAgedEast Asian PeopleFemaleHumansJapanMaleMiddle AgedSurveys and QuestionnairesTirzepatideGastric Inhibitory PolypeptideHypoglycemic AgentsTirzepatideFood behaviorJapanese foodLoss of appetiteNutritional therapyTirzepatideType 2 diabetes mellitus

Identifiers

PMID41462404
PMCPMC12750934

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.